Medical Physics Research Today is a free monthly online journal that collates and summarizes the latest research about Medical Physics, including details on medicine, radiotherapy, biomechanics, medical imaging.

Effect of the pyrrolopyrimidine lipid peroxidation inhibitor U-101033E on neuronal and astrocytic metabolism and infarct volume in rats with transient middle cerebral artery occlusion.

Håberg A, Qu H, Hjelstuen MH, Sonnewald U

Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, NTNU, Trondheim, Norway.

The aim of the present study was to assess the effect of post ictal administration of the pyrrolopyrimidine lipid peroxidation inhibitor, U-101033E, on infarct volume and neuronal and astrocytic metabolism in rats with transient middle cerebral artery occlusion (MCAO). Rats were subjected to 120min of MCAO followed by 140min of reperfusion and randomly assigned to control (n=17) or U-101033E treatment (n=16). Drug infusion started 5min after MCAO and lasted 220min with a 15min interruption during the reperfusion procedure. Sixteen rats underwent diffusion weighted imaging 260min after ictus, from which the apparent diffusion coefficient (ADC) was determined. Seventeen rats received an iv bolus injection of [1-(13)C]glucose and [1,2-(13)C]acetate 245min after ictus. Tissue extracts from two brain regions representing penumbra and ischemic core were analyzed with (13)C NMRS and HPLC. U-101033E did not affect the volume of ischemic tissue estimated from the ADC maps. In the penumbra, U-101033E specifically decreased mitochondrial pyruvate metabolism via both pyruvate dehydrogenase and pyruvate carboxylase pathways. Thus, U-101033E impaired both neuronal and astrocytic mitochondrial pyruvate metabolism. At the same time anaerobic glucose usage was increased, leading to increased lactate labeling and content. Also alanine labeling was increased. The data do not support lactate as an important substrate for neuronal mitochondria in ischemia-reperfusion. A similar pattern of reduced mitochondrial pyruvate metabolism and increased cytosolic pyruvate metabolism was found in the irreversibly damaged ischemic core. The present study highlights the importance of other outcome measures than ischemic tissue volume for evaluation of drug efficacy in animal models, which in turn could increase the likelihood of success in clinical trials.

Published 26 June 2007 in Neurochem Int, 50(7): 932-40.
Full-text of this article is available online (may require subscription).

© 2005-2008 Medical Physics Research Today. All Rights Reserved.